Novartis’s eye care divison Alcon has introduced a new intraocular lens (IOL) AcrySof IQ PanOptix Toric to correct presbyopia and astigmatism in patients with pre-existing corneal astigmatism undergoing cataract surgery.
The new IOL is designed for primary implantation in the capsular bag of the posterior chamber of the human eye, for the visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens or clear lens.
Astigmatism is a variation in the shape or curvature of the cornea, while cataract is a cloudy area in the natural lens of the eye that affects vision and Presbyopia occurs as a part of natural aging.
The lens will be indicated for patients with and without presbyopia undergoing cataract surgery, who seek to correct near, intermediate and distance vision with improved spectacle independence.
Alcon chief executive officer and division head Mike Ball said: “This lens not only expands available options physicians have to provide value to their patients with astigmatism, it gives patients the visual clarity and increased independence to improve their current lifestyles.
“For the surgeon, it also allows them to treat astigmatism at the same time as presbyopia with a trifocal that is part of the market-leading AcrySof platform.”
Expanding the firm’s PanOptix trifocal platform, the new IOL combines the same trifocal optic as the AcrySof IQ PanOptix IOL on the front surface with the astigmatic correction properties of a toric IOL on the back surface.
It enables an intermediate focal point at 60cm with rotational and axial stability of the AcrySof single piece design.
With CE mark received in last November, AcrySof IQ PanOptix Toric is currently available in Spain, Portugal and Chile.